Sign in

You're signed outSign in or to get full access.

Christine Klaskin

Treasurer at MiNK Therapeutics
Executive

About Christine Klaskin

Christine M. Klaskin, 59, serves as Treasurer of MiNK Therapeutics and has held this role since July 2017; she is also Vice President, Finance at Agenus (since October 2006), having joined Agenus in 1996 as a finance manager after prior service as an audit manager at Arthur Andersen. She holds a Bachelor of Accountancy from The George Washington University . Ms. Klaskin’s compensation for services to MiNK is allocated from Agenus and she does not receive compensation directly from MiNK; she was not eligible for a MiNK annual bonus for fiscal 2024 and held no MiNK equity awards as of December 31, 2024 . As of April 24, 2025, she beneficially owned 5,789 MiNK shares, less than 1% of the class .

Past Roles

OrganizationRoleYearsStrategic Impact
MiNK Therapeutics, Inc.TreasurerSince Jul 2017
Agenus Inc.Finance Manager1996–2006
Arthur AndersenAudit ManagerNot disclosed

External Roles

OrganizationRoleYearsNotes
Agenus Inc.Vice President, FinanceSince Oct 2006Compensation for services to MiNK is allocated from Agenus

Fixed Compensation

MetricFY 2023FY 2024
Salary allocated from Agenus for MiNK service ($)$29,624 $29,822
Bonus ($)— (not paid by MiNK) — (not yet determined for others; not eligible for Klaskin)
Stock awards ($)
Option awards ($)
All other compensation ($)
Total ($)$29,624 $29,822

Performance Compensation

ComponentMetricTargetActual/PayoutVesting
Annual bonus (MiNK)Not eligible for FY 2024
Equity awards (MiNK)None in FY 2024
  • For MiNK FY 2024 corporate context, the company set goals around clinical readouts, extending cash runway, scaling iNKT manufacturing, advancing combinations/engagers, and investor engagement; Ms. Klaskin was not eligible for a MiNK bonus for FY 2024 .

Equity Ownership & Alignment

MetricApr 17, 2024Dec 16, 2024Apr 24, 2025
Shares owned55,660 57,905 5,789
Shares issuable (options/RSUs within 60 days)
Percent of class<1% <1% <1%
  • Company equity awards outstanding: None held by Ms. Klaskin as of December 31, 2024 .
  • Reverse stock split: MiNK effected a 1-for-10 reverse split on January 28, 2025, reflected in disclosures of option exercise prices and share counts elsewhere in the proxy .
  • Pledging/hedging: MiNK maintains a Code of Ethics and a Securities Trading Policy (updated March 2023); no pledging or hedging by Ms. Klaskin is disclosed in the proxy .

Employment Terms

TermDetail
Employment agreement with MiNKNone; Ms. Klaskin is also a named executive officer of Agenus; a portion of her Agenus compensation is allocated to MiNK
Severance (MiNK)None; MiNK does not provide severance or change-in-control benefits to Ms. Klaskin
Change-in-control (MiNK CIC Plan)CIC Plan covers certain employees (VP+), e.g., CEO; Ms. Klaskin is not covered and has no CIC benefits at MiNK
Bonus eligibility (MiNK FY 2024)Not eligible
Compensation determinationDetermined by Agenus and its compensation committee for her role at Agenus; MiNK does not directly compensate her

Investment Implications

  • Compensation alignment: Klaskin’s pay is determined by Agenus and not directly by MiNK; she had no MiNK bonus eligibility and no MiNK equity awards in FY 2024, limiting direct pay-for-performance alignment and reducing vesting-driven selling pressure at MiNK .
  • Ownership skin-in-the-game: Beneficial ownership is de minimis (<1% across periods), suggesting limited direct equity alignment relative to core MiNK executives .
  • Retention and transition risk: Absence of MiNK severance/change-in-control economics reduces MiNK-specific retention hooks; continuity risk for the Treasurer function is more dependent on Agenus’s employment terms and priorities, given her dual role and compensation source .
  • Governance/controls: MiNK’s Code of Ethics and Securities Trading Policy are in place; no red flags disclosed regarding pledging/hedging or related-party transactions tied to Klaskin in the proxy excerpts reviewed .